These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37531737)

  • 1. Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center.
    Thibodeau S; Meem M; Hopman W; Sandhu S; Zalay O; Fung AS; Kartolo A; Digby GC; Al-Ghamdi S; Robinson A; Ashworth A; Owen T; Mahmud A; Tam K; Olding T; de Moraes FY
    Cancer Treat Res Commun; 2023; 36():100747. PubMed ID: 37531737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
    Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
    Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
    Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
    Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
    Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
    Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
    Desilets A; Blanc-Durand F; Lau S; Hakozaki T; Kitadai R; Malo J; Belkaid W; Richard C; Messaoudene M; Cvetkovic L; Kazandjian S; Tehfe M; Florescu M; Jao K; Daaboul N; Owen S; Shieh B; Agulnik J; Cohen V; Charbonneau C; Marcoux N; Blais N; Leighl NB; Bradbury PA; Liu G; Shepherd FA; Bahig H; Routy B; Sacher A; Elkrief A
    Eur J Cancer; 2021 Jan; 142():83-91. PubMed ID: 33242835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
    Peled N; Roisman LC; Levison E; Dudnik J; Chernomordikov E; Heching N; Dudnik E; Keren-Rosenberg S; Nechushtan H; Salhab A; Hershkovitz D; Tsuriel S; Hannes V; Rotem O; Lazarev I; Lichtenberg R; Granot IS; Krayim B; Shalata W; Levin D; Krutman Y; Allen AM; Blumenfeld P; Lavrenkov K; Kian W
    Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):105-114. PubMed ID: 36925073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection.
    Taylor NA; Liao ZX; Cox JD; Stevens C; Roth J; Walsh G; Chang JY; Guerrero T; Jeter M; Putnam J; Fossella FV; Allen P; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):204-12. PubMed ID: 14697440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysis.
    Joosten PJM; Dickhoff C; van der Noort V; Smeekens M; Numan RC; Klomp HM; van Diessen JNA; Belderbos JSA; Smit EF; Monkhorst K; Oosterhuis JWA; van den Heuvel MM; Dahele M; Hartemink KJ
    Interact Cardiovasc Thorac Surg; 2022 Mar; 34(4):566-575. PubMed ID: 34734237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
    Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
    Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer.
    Wang Y; Zhang T; Wang J; Zhou Z; Liu W; Xiao Z; Deng L; Feng Q; Wang X; Lv J; Ma X; Xue Q; Wang J; Wang Z; Bi N
    Int J Radiat Oncol Biol Phys; 2023 Jul; 116(3):590-600. PubMed ID: 36623605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health care disparities among octogenarians and nonagenarians with stage III lung cancer.
    Cassidy RJ; Zhang X; Switchenko JM; Patel PR; Shelton JW; Tian S; Nanda RH; Steuer CE; Pillai RN; Owonikoko TK; Ramalingam SS; Fernandez FG; Force SD; Gillespie TW; Curran WJ; Higgins KA
    Cancer; 2018 Feb; 124(4):775-784. PubMed ID: 29315497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer.
    Kumar S; Feddock J; Li X; Shearer AJ; Hall L; Shelton BJ; Arnold S; McGarry RC
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):652-659. PubMed ID: 29280459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Couñago F; Rodriguez de Dios N; Montemuiño S; Jové-Teixidó J; Martin M; Calvo-Crespo P; López-Mata M; Samper-Ots MP; López-Guerra JL; García-Cañibano T; Díaz-Díaz V; de Ingunza-Barón L; Murcia-Mejía M; Alcántara P; Corona J; Puertas MM; Chust M; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Taboada B
    Lung Cancer; 2018 Apr; 118():119-127. PubMed ID: 29571989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: A National Cancer Database analysis.
    Limonnik V; Abel S; Finley GG; Long GS; Wegner RE
    Lung Cancer; 2020 Dec; 150():107-113. PubMed ID: 33126090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.